Добавил:
Upload Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:

Роль цитокинов в патогенезе злокачественных новообразований

.pdf
Скачиваний:
49
Добавлен:
16.02.2016
Размер:
615.55 Кб
Скачать

80.Boehm U. Cellular responses to interferon-gamma / U. Boehm, T. Klamp, M. Groot, J. C. Howard // Annu. Rev. Immunol. – 1997. – Vol. 15. – P. 749–795.

81.Boom W. H. Heterogeneity of helper / inducer T lymphocytes. II. Effects of interleukin 4- and interleukin 2-producing T cell clones on resting B lymphocytes / W. H. Boom, D. Liano, A. K. Abbas // J. Exp. Med. – 1988. –Vol. 167. – N 4. – P. 1350–1363.

82.Borden E. C. Interferons at age 50: past, current and future impact on biomedicine / E. C. Borden, G. C. Sen, G. Uze et al. // Nat. Rev. Drug. Discov. – 2007. – Vol. 6. – N 12. – P. 975–990.

83.Brandt E. Enhanced production of IL-8 in chronic but not in early ileal lesions of Crohn’s disease (CD) / E. Brandt, J. F. Colombel,

N.Ectors et al. // Clin. Exp. Immunol. – 2000 – Vol. 122. – N 2. –

P.180–185.

84.Brat D. J. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis / D. J. Brat, A. C. Bellail, E. G. Van Meir // Neuro-oncol. – 2005. – Vol. 7. – N 2. – P. 122–133.

85.BrarS. S.AnNAD(P)Hoxidaseregulatesgrowthandtranscription in melanoma cells / S. S. Brar, T. P. Kennedy, A. B. Sturrock et al. // Am. J. Physiol. Cell Physiol. – 2002. – Vol. 282. – N 6. –

P.С1212–С1224.

86.Brereton C. F. Inhibition of ERK MAPK suppresses IL-23– and IL-1–driven IL-17 production and attenuates autoimmune disease / C. F. Brereton, C. E. Sutton et al. // J. Immunol. – 2009. – Vol. 183. – N 3. – P. 1715–1723.

87.Bru A. Pinning of tumoral growth by enhancement of the immune response / A. Bru, S. Albertos, J. A. Lopez Garcia-Asenjo, I. Bru // Phys. Rev. Lett. – 2004. – Vol. 92. – N 23. – P. 238101–238104.

88.Bugeon L. Cutting edge: Notch signaling induces a distinct cytokine profile in dendritic cells that supports T cell-mediated regulation and IL-2–dependent IL-17 production / L. Bugeon, L. M. Gardner, A. Rose et al. // J. Immunol. – 2008. –Vol. 181. – N 12. – P. 8189–8193.

89.Burchill M. A. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis / M. A. Burchill, J. Yang, K. B. Vang, M. A. Farrar // Immunol. Lett. – 2007. – Vol. 114. – N 1. – P. 1–8.

90.Burstein H. J. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin / cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study / H. J. Burstein, L. N. Harris, R. Gelman et al. // J. Clin. Oncol. – 2003. – Vol. 21. – N 1. – P. 46–53.

91.Burstein E. Colitis and cancer: a tale of inflammatory cells and their cytokines / E. Burstein, E. R. Fearon // J. Clin. Invest. – 2008. – Vol. 118. – N 2. – Р. 464–467.

92.Butcher D. T. A tense situation: forcing tumour progression / D. T. Butcher, T. Alliston, V. M. Weaver // Nat. Rev. Cancer. – 2009. – Vol. 9. – N 2. – P. 108–122.

51

93.Cao R. Interleukin-18 acts as an angiogenesis and tumor suppressor / R. Cao, J. Farnebo, M. Kurimoto, Y. Cao // FASEB. J. – 1999. – Vol. 13. – P. 2195–2202.

94.Campbell L. L. Breast tumor heterogeneity: cancer stem cells or clonal evolution? / L. L. Campbell, K. Polyak // Cell Cycle. – 2007. – Vol. 6. – N 19. – P. 2332–2338.

95.Campoli M. HLA class I antigen loss, tumor immune escape and immune selection / M. Campoli, C. C. Chang, S. Ferrone // Vaccine. – 2002. – Vol. 20. – Suppl. 4. – P. A40–А45.

96.Carpentier I. Function and regulation of tumor necrosis factor type 2 / I. Carpentier, B. Coornaert, R. Beyaert // Curr. Med. Chem. – 2004. – Vol. 11. – P. 2205–2212.

97.CarrascalM. T.Interleukin-18bindingproteinreducesb16melanoma hepatic metastasis by neutralizing adhesiveness and growth factors of sinusoidal endothelium / M. T. Carrascal, L. Mendoza, M. Valcarcel et al. // Cancer Res. – 2003. – Vol. 63. – N 2. – P. 491–497.

98.Casiano C. A. Tumor-associated antigen arrays for the serological diagnosis of cancer / C. A. Casiano, M. Mediavilla-Varela, E. M. Tan // Mol. Cell. Proteomics. – 2006. – Vol. 5. – N 10. – P. 1745–1759.

99.Carswell E. A. An endotoxin induced serum factor that causes necrosis of tumors / E. A. Carswell, L. J. Old, R. L. Kassel et al. // Proc. Natl. Acad. Sci. U. S. A. – 1975. – Vol. 72. – P. 3666–3670.

100.Chan C. W. The ‘kiss of death’ by dendritic cells to cancer cells / C. W.Chan,F.Housseau//CellDeath.Differ. –2008. –Vol.15. –N1. – P. 58–69.

101.Chang C. Y. Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model / C. Y. Chang, J. Lee, E. Y. Kim et al. // BMC Cancer. – 2007. – Vol. 7. – P. 87.

102.Charo I. F. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails / I. F. Charo, S. J. Myers, A. Herman // Proc. Natl. Acad. Sci. U S A. – 1994 – Vol. 91. – N 7. – P. 2752–2756.

103.Chen H. TGF-beta induces fibroblast activation protein expression; fibroblast activation protein expression increases the proliferation, adhesion, and migration of HO-8910 PM / H. Chen, WW. . Yang, Q. T. Wen et al. // Exp. Mol. Pathol. – 2009. – Vol. 87. – N 3. – P. 189–194.

104.ChengG. Z.AdvancesofAKTpathwayinhumanoncogenesisandasa targetforanti-cancerdrugdiscovery/G. Z.Cheng,S.Park,S.Shuetal.// Curr. Cancer. Drug. Targets. – 2008. – Vol. 8. – P. 2–6.

105.Cheng L. E. Enhanced signaling through the IL-2Receptor in CD8+ T cells regulated by antigen recognition results in preferential proliferation and expansion of responding CD8+ T cells rather than promotion of cell death / L. E. Cheng, C. Ohlén, B.H . Nelson, P. D. Greenberg // Proc. Natl. Acad. Sci. U S A.–  2002. – Vol. 99. – N 5. – P. 3001–3006.

52

106.Chi D. S. MAPK-dependent regulation of IL-1– and beta-adrenore- ceptor-induced inflammatory cytokine production from mast cells: implications for the stress response / D. S. Chi, S. M. Fitzgerald,

S.Pitts et al. // BMC Immunol. – 2004. – Vol. 5. – P. 22.

107.Chizzolini C. Prostaglandin E2 synergistically with interleukin-23 favors human Th17 expansion / C. Chizzolini, R. Chicheportiche,

M.Alvarez et al. // Blood. – 2008. – Vol. 112. – P. 3696–3703.

108.Cho J. H. An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2 / J. H. Cho, O. Boyman, H. O. Kim et al. // J. Exp. Med. – 2007. – Vol. 204. – N 8. – P. 1787–1801.

109.Cohen S. Similarities of T cell function in cellmediated immunity and antibody production / S. Cohen, P. E. Bigazzi, T. Yoshida // Cell. Immunol. – 1974. – Vol. 2. – P. 150–159.

110.Colon and rectum // American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6 th ed. NY, Springer. – 2002. – P. 113–124.

111.Crepaldi L. Molecular basis of the synergistic production of IL-1 receptor antagonist by human neutrophils stimulated with IL-4 and IL-10 / L. Crepaldi, L. Silveri, F. Calzetti et al. // Int. Immunol. – 2002. – Vol. 14. – N 10. – P. 1145–1153.

112.Cressey R. Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis / R. Cressey, O. Wattananupong, N. Lertpra-sertsuke,

U.Vinitketkumnuen // BMC Cancer. – 2005. – Vol. 5. – P. 128.

113.Crimeen-Irwin B. Failure of immune homeostasis – the consequences of under and over reactivity / B. Crimeen-Irwin, K. Scalzo, S. Gloster etal.//Curr.Drug.Targets.Immune.Endocr.Metabol.Disord. –2005. – Vol. 5. – N 4. – P. 413–422.

114.De Groote D. Ex vivo cytokine production by whole blood cells from cancer patients / D. De Groote, Y. Gevaert, M. Lopez et al. // Cancer. Detect. Prev. – 1996. – Vol. 20. – N 3. – P. 207–213.

115.De Vita F. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma / F. De Vita,

M.Orditura, E. Lieto et al. // Cancer. – 2004. – Vol. 100. – P. 270–278.

116.Dhodapkar M. V. Interactions of tumor cells with dendritic cells: balancing immunity and tolerance / M. V. Dhodapkar, K. M. Dhodapkar, A. K. Palucka // Cell Death Differ. – 2008. – Vol. 15. – N 1. – P. 39–50.

117.Dinarello C. A. Blocking IL-1 in systemic inflammation. / C. A. Dinarello // J. Exp. Med. – 2005. – Vol. 201. – N 9. – P. 1355–1359.

118.Dinarello C. A. Why not treat human cancer with interleukin-1 blockade? / C. A. Dinarello // Cancer Metastasis Rev. – 2010. – Vol. 29. – N 2. – P. 317–329.

119.Dinarello C. A. Interleukin-18, a proinflammatory cytokine / C. A. Dinarello // Eur. Cytokine. Netw. – 2000. – Vol. 11. – N 3. – P. 483–486.

120.Dinarello C. A. Targeting interleukin 18 with interleukin 18 binding protein / C. A. Dinarello // Ann. Rheum. Dis. – 2000. – Vol. 59. – Suppl. 1. – P. i17–i20.

53

121.Dinarello C. A. Novel targets for interleukin 18 binding protein / CA. . Dinarello // Ann. Rheum. Dis.–  2001. – Vol. 60. – Suppl. 3. – P. iii18– iii24.

122.Dinarello C. A. The paradox of pro-inflammatory cytokines in cancer / C. A. Dinarello // Cancer Metastasis Rev. – 2006. – Vol. 25. – P. 307–313.

123.Di Vizio D. Skp2 expression is associated with high risk and elevated Ki67 expression in gastrointestinal stromal tumours / D. Di Vizio,

F.Demichelis, S. Simonetti et al. // BMC Cancer.–  2008. – Vol. 8. – P. 134.

124.Dudler J. Gene transfer of interleukin-18–binding protein attenuates cardiac allograft rejection / J. Dudler, E. Simeoni, S. Fleury et al. // Transpl. Int. – 2007. – Vol. 20. – N 5. – P. 460–466.

125.Dummer R. Long-term pegylated interferon-alpha and its potential in the treatment of melanoma / R. Dummer, J. Mangana // Biologics. – 2009. – Vol. 3. – P. 169–182.

126.Elaraj D. M. The role of interleukin 1 in growth and metastasis ofhumancancerxenografts/D. M.Elaraj,D. M.Weinreich,S.Varghese et al // Clin. Cancer Res. – 2006. – Vol. 12. – P. 1088–1096.

127.Eldesoky A. Clinical relevance of serum vascular endothelial growth factor and Interleukin-6 in patients with colorectal cancer / A. Eldesoky, A. Shouma, Y. Mosaad, A. Elhawary // Saudi. J. Gastroenterol. – 2011. – Vol. 17. – N 3. – P. 170–173.

128.Erreni M. Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer / M. Erreni, A. Mantovani, P. Allavena // Cancer Microenviron. – 2011. – Vol. 4. – N 2. – P. 141–154.

129.Essner R. IL-4 downregulates IL-1 and TNF gene expressionin human monocytes / R. Essner, K. Rhoades, W. H. McBride et al. // J. Immunol. – 1989. – Vol. 142. – P. 3857–3861.

130.Esteban F. MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up / F. Esteban, M. Redondo, M. Delgado et al. // Br.  J. Cancer. – 1996. – Vol. 74. – N 11. – 1801–1804.

131.Eun J. Sohna. Bacterial lipopolysaccharide stimulates bovine neutrophil production of TNF-α, IL-1 β, IL-12 and IFN-γ / Eun J. Sohna, Max J. Paapeb et al. // Vet. Res. – 2007. – Vol. 38

132.Evans C. The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival / C. Evans, I. Morrison, A. G. Heriot et al. // Br.  J. Cancer. – 2006. – Vol. 94. – N 10. – P. 1412–1419.

133.Ferrero-Miliani L. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1 beta generation / L. Ferrero-Miliani, O.H Nielsen, P.S Andersen, S. E. Girardin // Clin. Exp. Immunol. – 2007. – Vol. 147. –

P.227–235.

134.Finkelman F. D. Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes / F. D. Finkelman, K. B. Madden, S. C. Morris et al. // J. Immunol. – 1993. – Vol. 151. – N 3. –

P.1235–1244.

54

135.Fischer J. R. Selective suppression of cytokine secretion in patients with small-cell lung cancer / J. R. Fischer, M. Schindel, N. Stein et al.

//Ann. Oncol. – 1995. – Vol. 6. – N 9. – P. 921–926.

136.Foran J. M. Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis / J. M. Foran, A. J. Norton, I. N. Micallef et al. // Br. J. Haematol. – 2001. – Vol. 114. – N 4. – P. 881–883.

137.Frankel B. Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion / B. Frankel, S. L. Longo, G. W. Canute // J. Neurooncol. – 2000. – Vol. 48. – N 1. – P. 21–26.

138.Francipane M. G. Crucial role of interleukin-4 in the survival of colon cancer stem cells / M. G. Francipane, M. P. Alea, Y. Lombardo et al. // Cancer Res. – 2008. – Vol. 68. – N 11. – P. 4022–4025.

139.Frey A. B. Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response / A. B. Frey, N. Monu //

J.Leukoc. Biol. – 2006. – Vol. 79. – N 4. – P. 652–662.

140.Fridlender Z. G. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN / Z. G. Fridlender, J. Sun,

S.Kim et al. // Cancer Cell. – 2009. – Vol. 16. – N 3. – P. 183–194.

141.Fu S. L. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells / S. L. Fu, J. Pierre, T. A. Smith-Norowitz et al.

//Clin. Exp. Immunol. – 2008. – Vol. 153. – N 3. – P. 401–409.

142.Fyfe G. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy / G. Fyfe, R. I. Fisher, S. A. Rosenberg et al. // J. Clin. Oncol. – 1995. – Vol. 13. – P. 688–696.

143.Gao X. D. Inhibition of telomerase with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells / X. D. Gao, Y. R. Chen // Asian J. Androl. – 2007. – Vol. 9. – N 5. – P. 697–704.

144.Gao F. Dysfunction of murine dendritic cells induced by incubation with tumor cells / F. Gao, X. Hui, X. He et al. // Cell Mol. Immunol. – 2008. – Vol. 5. – N 2. – P. 133–140.

145.Gatenby R. A. An evolutionary model of carcinogenesis / R. A. Gatenby, T. L. Vincent // Cancer Res. – 2003. – Vol. 63. – N 19. – P. 6212–6220.

146.Gerritsma J. S. Regulation and production of IL-8 by human proximal tubular epithelial cells in vitro / J.S . Gerritsma, P. S. Hiemstra, A. F. Gerritsen et al. // Clin. Exp. Immunol.–  1996 – Vol. 103 –N 2 – P. 289–294.

147.Gerlini G. Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions / G. Gerlini, A. Tun-Kyi, C. Dudli et al. // Am. J. Pathol. – 2004. – Vol. 165. – N 6. – P. 1853–1863.

148.Gesser B. IL-8 induces T cell chemotaxis, suppresses IL-4, and up-regulates IL-8 production by CD4+ T cells / B. Gesser,

55

 

M. Lund, N. Lohse et al. // J. Leukoc. Biol. – 1996. – Vol. 59. –

149.

N 3. – P. 407–411.

Giacomelli L. Persistence of epidermal growth factor receptor and

 

interleukin 10 in blood of colorectal cancer patients after surgery

 

identifies patients with high risk to relapse / L. Giacomelli,

 

W.Gianni,C.Belfioreetal.//Clin.CancerRes. –2003. –Vol.9. –N7. –

150.

P. 2678–2682.

Giannelli G. Biological and clinical significance of neutralizing and

 

bindingantibodiestointerferon-alpha(IFN-alpha)duringtherapyfor

 

chronic hepatitis C / G. Giannelli, G. Antonelli, G. Fera et al. // Clin.

151.

Exp. Immunol. – 1994. – Vol. 97. – N 1. – P. 4–9.

Gilli F. Neutralizing antibodies against IFN-beta in multiple

 

sclerosis:antagonizationofIFN-betamediatedsuppressionofMMPs/

 

F. Gilli, A. Bertolotto, A. Sala et al. // Brain. – 2004. – Vol. 127. – N 2. –

152.

P. 259–268.

Goto S. Analysis of Th1 and Th2 cytokine production by peripheral

 

blood mononuclear cellsas a parameter of immunologicaldysfunction

 

in advanced cancer patients / S. Goto, M. Sato, R. Kaneko et al. //

153.

Cancer Immunol. Immunother. – 1999. – Vol. 48. – N 8. – P. 435–442.

Gougerot-Pocidalo M. A. Regulation of human neutrophil oxidative

 

burstbypro-andanti-inflammatorycytokines/M. A.Gougerot-Pocidalo,

 

J. el Benna, C. Elbim et al. // J. Soc. Biol. – 2002. – Vol. 196. – N 1. –

154.

P. 37–46.

Grutz G. New insights into the molecular mechanism of

 

interleukin-10–mediated immunosuppression / G. Grutz // J. Leukoc.

155.

Biol. – 2005. – Vol. 77. – N 1. – P. 3–15.

Gui J. Effects of acupuncture on Th1, Th2 cytokines in rats of

 

implantation failure / J. Gui, F. Xiong, J. Li, G. Huang // Evid. Based.

156.

Complement. Alternat. Med. – 2012. – Vol. 2012. – P. 893023.

Hagemann T. Macrophages induce invasiveness of epithelial cancer

 

cells via NF-kappa B and JNK / T. Hagemann, J. Wilson, H. Kulbe

157.

et al. // J. Immunol. – 2005. – Vol. 175. – P. 1197–1205.

Haggar F. A. Colorectal cancer epidemiology: incidence, mortality,

 

survival, and risk factors / F. A. Haggar, R. P. Boushey // Clin. Colon.

158.

Rectal. Surg. – 2009. – Vol. 22. – N 4. – Р. 191–197.

Halin S. Extratumoral macrophages promote tumor and vascular

 

growth in an orthotopic rat prostate tumor model / S. Halin, S. H.

 

Rudolfsson, N. Van Rooijen, A. Bergh // Neoplasia. – 2009. – Vol. 11. –

159.

N 2. – P. 177–186.

Hansen M. B. Transfusion-related inhibition of cytokines (TRICK).

 

Experimentaltransferofneutralizingautoantibodiestointerleukin-6

 

by plasma transfusions / M. B. Hansen, P. Galle, M. Salomo et al. //

160.

Vox Sang. – 2007. – Vol. 92. – N 3. – P. 213–223.

Hao N. B. Macrophages in tumor microenvironments and the

 

progression of tumors / N. B. Hao, M. H. Lü, Y. H. Fan et al. // Clin.

 

Dev. Immunol. – 2012. – Vol. 2012. – P. 948098.

56

161.Hardy R. G. ABC of colorectal cancer: molecular basis for risk factors / R. G. Hardy, S. J. Meltzer, J. A. Jankowski // BMJ. – 2000. – Vol. 321. –

P.886–889.

162.Hatanaka E. Neutrophils and monocytes a spotentially important sources of proinflammatory cytokines in diabetes / E. Hatanaka, P. T. Monteagudo, M. S. Marrocos, A. Campa // Clin. Exp. Immunol. – 2006. – Vol. 146. – N 3. – P. 443–447.

163.Haudenschild D. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer / D. Haudenschild, T. Moseley, L. Rose, A. H. Reddi

//J. Biol. Chem. – 2002. – Vol. 277. – N 6. – P. 4309–4316.

164.He Z. Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury / Z. He, L. Lu, C. Altmann et al. // Am. J. Physiol. Renal Physiol. – 2008. – Vol. 295. – N 5. – P. F1414–F1421.

165.Herbeuval J. P. Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6 / J. P. Herbeuval, E. Lelievre, C. Lambert et al. // Immunol. – 2004. – Vol. 172. – N 7. – Р. 4630–4636.

166.Heriot A. G. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection / A.G . Heriot, J. B. Marriott, S. Cookson et al. // Br.  J. Cancer. – 2000. – Vol. 82. – N 5. – P. 1009–1012.

167.Hess S. Loss of IL-6 receptor expression in cervical carcinoma cellsinhibits autocrine IL-6 stimulation: abrogation ofconstitutive monocyte chemoattractant protein-1 production / S. Hess, H. Smola, U. Sandaradura De Silva et al. // J. Immunol.–  2000. – Vol. 165.– P. 1939–1948.

168.Höfer T. Competition for IL-2 between Regulatory and Effector T Cells to Chisel Immune Responses / T. Höfer, O. Krichevsky,

G.Altan-Bonnet // Front. Immunol. – 2012. – Vol. 3. – P. 268.

169.Hoffmann P. R. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo / P.R . Hoffmann, J. A. Kench, A. Vondracek et al. // J. Immunol.–  2005. – Vol. 174. – N 3. – P. 1393–1404.

170.HoltanS. G.Cancerandpregnancy:parallelsingrowth,invasion,and immune modulation and implications for cancer therapeutic agents / S. G. Holtan, D. J. Creedon, P. Haluska, S. N. Markovic // Mayo Clin. Proc. – 2009. – Vol. 84. – N 11. – P. 985–1000.

171.Hong D. S. Interleukin-6 and its receptor in cancer: implications for Translational Therapeutics / D. S. Hong, L. S. Angelo, R. Kurzrock // Cancer. – 2007. – Vol. 110. – N 9. – P. 1911–1928.

172.Honorati M. C. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts / M. C. Honorati, S. Neri, L. Cattini, A. Facchini

//Osteoarthritis Cartilage. – 2006. – Vol. 14. – P. 345–352.

173.Horiuchi T. Transmembrane TNF-α: structure, function and interaction with anti-TNF agents / T. Horiuchi, H. Mitoma, S. Harashima et al. // Rheumatology. – 2010. – Vol. 49. – N 7. – P. 1215–1228.

57

174.Hsu T. C. Transformation nonresponsive cells owe their resistance to lack of p65 / nuclear factor-kappaB activation / T. C. Hsu, R. Nair,

P.Tulsian et al. // Cancer Res. – 2001. – Vol. 61. – P. 4160–4168.

175.Hu M. Overlapping gene expression in fetal mouse intestine development and human colorectal cancer / M. Hu, R. A. Shivdasani // Cancer Res. – 2005. – Vol. 65. – N 19. – P. 8715–8722.

176.Huang X. Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-β / X. Huang, C. Lee // Front. Biosci. – 2003. – Vol. 8. –

P.740–749.

177.Hwang S. Y. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3–kinase / Aktdependent pathways / S. Y. Hwang, J. Y. Kim, K. W. Kim et al. // Arthritis. Res. Ther. – 2004. – Vol. 6. – N 2. – P. 120–128.

178.Hyzdalova M. The interaction of butyrate with TNF-alpha during differentiation and apoptosis of colon epithelial cells: role of NF-kap- paB activation / M. Hyzdalova, J. Hofmanova, J. Pacherník et al. // Cytokine. – 2008. – Vol. 44. – N 1. – P. 33–43.

179.Isaacs A. Virus interference. I. The interferon / A. Isaacs, J. Lindenmann // Proc. R. Soc. Lond. B. Biol. Sci. – 1957. – Vol. 147. – P. 258–267.

180.Ishida Y. The role of IL-18 in the modulation of matrix metalloproteinases and migration of human natural killer (NK) cells / Y. Ishida,

K.Migita, Y. Izumi et al. // FEBS Lett. – 2004. – Vol. 569. – N 1–3. –

P.156–160.

181.Ikeda H. The roles of IFN gamma in protection against tumor development and cancer immunoediting / H. Ikeda, L.J . Old, R. D. Schreiber // Cytokine Growth Factor Rev. – 2002. – Vol. 13. – N 2. – P. 95–109.

182.Ito M. Tumor-derived TGFbeta-1 induces dendritic cell apoptosis in the sentinel lymph node / M. Ito, Y. Minamiya, H. Kawai et al. //

J.Immunol. – 2006. – Vol. 176. – N 9. – P. 5637–5643.

183.Ishikawa F. New biodefense strategies by neutrophils / F. Ishikawa,

S.Miyazaki // Arch. Immunol. Ther. Exp. (Warsz). – 2005. – Vol. 53. – N 3. – P. 226–233.

184.Iwagaki H. Interleukin-1 receptor antagonists and other markers in colorectal cancer patients / H. Iwagaki, A. Hizuta, N. Tanaka // Scand. J. Gastroenterol. – 1997. – Vol. 32. – N 6. – P. 577–581.

185.Jain S. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer / S. Jain, G. Chakraborty, R. Raja et al. // Cancer Res. – 2008. – Vol. 68. – N 19. – P. 7750–7759.

186.JeffeF.AdenosineandIFN-{alpha}synergisticallyincreaseIFN-gam- ma production of human NKcells / F. Jeffe, Stegmann K.A. et al. //

J.Leukoc. Biol. – 2009. – Vol. 85. – N 3. – P. 452–461.

187.Jeon S. H. Mechanisms underlying TGF-β1–induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis / S. H. Jeon, B. C. Chae, H. A. Kim et al. // J. Leukocyte Biol. – 2007. – Vol. 81. – P. 557–566.

58

188.JiangH.Howtheimmunesystemachievesself-nonselfdiscrimination during adaptive immunity / H. Jiang, L. Chess // Adv. Immunol. – 2009. – Vol. 102. – P. 95–133.

189.Jiang J. Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors / J. Jiang, M. S. Jin, J. Suo et al. // World J. Gastroenterol. – 2012. – Vol. 18. – N 20. – Р. 2569–2575.

190.Jiménez-Sainz M. C. Signaling pathways for monocyte chemoattractant protein 1–mediated extracellular signal-regulated kinase activation / M. C. Jiménez-Sainz, B. Fast, F.Jr. Mayor, A. M. Aragay // Mol. Pharmacol. – 2003. – Vol. 64. – N 3. – P. 773–782.

191.JohnsonC.Interleukin-6anditsreceptor,keyplayersinhepatobiliary inflammation and cancer / C. Johnson, Y. Han, N. Hughart et al. // Transl. Gastrointest. Cancer. – 2012. – Vol. 1. – N 1. – P. 58–70.

192.Johnston D. A. TNF induction of jagged-1 in endothelial cells is NFkappaB-dependent / D. A. Johnston, B. Dong, C. C. Hughes // Gene. – 2009. – Vol. 435. – P. 36–44.

193.Jonasch E. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities / E. Jonasch, F. G. Haluska

//Oncologist. – 2001. – Vol. 6. – P. 34–55.

194.Jones S. A. Therapeutic strategies for the clinical blockade of IL-6 / gp130 signaling / S. A. Jones, J. Scheller, S. Rose-John // J. Clin. Invest. – 2011. – Vol. 121. – P. 3375–3383.

195.Ju D. W. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates / D. W. Ju, Q. Tao,

G.Lou // Cancer Res. – 2001. – Vol. 61. – P. 3735–3740.

196.Ju W. A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells / W. Ju, X. Wang,

H.Shi et al. // Mol. Pharmacol.–  2007. – Vol. 71. – N 5. – P. 1381–1388.

197.Juge-Aubry C. E. Regulatory effects of interleukin (IL)-1, interferonbeta, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue / C. E. Juge-Aubry, E. Somm et al. // J. Clin. Endocrinol. Metab. – 2004. – Vol. 89. – N 6. – P. 2652–2658.

198.Jung M. K. IL-18 enhances the migration ability of murine melanoma cellsthroughthegenerationofROIandtheMAPKpathway/M. K.Jung, H. K.Song,K. E.Kimetal.//Immunol.Lett. –2006. –Vol.107. –N2. –

P.125–130.

199.Jussila L. Lymphatic endothelium and Kaposi’s sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3 / L. Jussila, R. Valtola, T. A. Partanen et al. // Cancer Res. – 1998. – Vol. 58. – N 8. – P. 1599–1604.

200.Kaler P. Tumor associated macrophages protect colon cancer cells from TRAIL-induced apoptosis through IL-1 β- dependent stabilization of snail in tumor cells / P. Kaler, V. Galea, L. Augenlicht,

L.Klampfer // PLoS One. – 2010. – Vol. 5. – N 7. – P. e11700.

59

201.KalerP.TheNF-kappaB/AKT-dependentInductionofWntSignaling in Colon Cancer Cells by Macrophages and IL-1 beta / P. Kaler, B. N. Godasi, L. Augenlicht, L. Klampfer // Cancer Microenviron. – 2009. – Vol. 2. – N 1. – P. 69–80.

202.Kamińska J. CRP, TNF-alpha, IL-1 ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients / J. Kamińska, M. M. Kowalska, M. P. Nowacki et al. // Pathol. Oncol. Res. – 2000. – Vol. 6. – N 1. –

P.38–41.

203.Kang J. S. Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44 / J. S. Kang, S. Y. Bae, H. R. Kim et al // Carcinogenesis. – 2009. – Vol. 30. – N 12. – P. 1987–1996.

204.Kannanganat S. Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells /

S.Kannanganat, C. Ibegbu, L. Chennareddi et al. // J. Virol. – 2007. – Vol. 81. – N 16. – P. 8468–8476.

205.KawaidaH.DistributionofCD4+CD25highregulatoryT-cellsintumor- draining lymph nodes in patients with gastric cancer / H. Kawaida,

K.Kono, A. Takahashi et al. // J. Surg. Res. – 2005. – Vol. 124. – N 1. –

P.151–157.

206.Kawakami K. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy / K. Kawakami, M. Kawakami, R. K. Puri // Crit. Rev. Immunol. – 2001. – Vol. 21. – P. 299–310.

207.Kehlen A. Interleukin-17 stimulates the expression of IκBα mRNA andthesecretionofIL-6andIL-8inglioblastomacelllines/A.Kehlen,

K.Thiele, D. Riemann et al. // J. Neuroimmunol. – 1999. – Vol. 101. –

P.1–6.

208.Kimata H. Interleukin 8 (IL-8) selectively inhibits immunoglobulin E production induced by IL-4 in human B cells / H. Kimata, A. Yoshida,

C.Ishioka et al. // J. Exp. Med.–  1992. – Vol. 176. – N 4. – P. 1227–1231.

209.Kim D. K. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer / D. K. Kim, S. Y. Oh, H. C. Kwon et al. // BMC Cancer. – 2009. – Vol. 9. –

P.155.

210.Kim J. IL-18 enhances thrombospondin-1 production in human gastric cancer via JNK pathway / J. Kim, C. Kim, T. S. Kim et al. // Biochem. Biophys. Res. Commun. – 2006. – Vol. 344. – N 4. –

P.1284–1289.

211.Kim K. E. Expression of ADAM33 is a novel regulatory mechanism in IL-18–secreted process in gastric cancer / K. E. Kim, H. Song, C. Hahm et al. // J. Immunol. – 2009. – Vol. 182. – N 6. – P. 3548–3555.

212.Kim K. E. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines / K. E. Kim, H. Song, T. S. Kim et al. // Oncogene. – 2007. – Vol. 26. – N 10. – P. 1468–1476.

60